drugset
drugset / Trial / NCT07218887

ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy

NCT07218887 ↗

Phase 1/2 Recruiting 6 enrolled Alexion Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This Phase 1/2 study is an open-label, dose finding and dose expansion study investigating the safety, tolerability, and efficacy of a single IV infusion of ALXN2350 in adult participants with BAG3 associated DCM.

Timeline

Start
2025-10-24
Primary completion
2032-01-27
Completion
2032-01-27

Drugs

EvaluationDrugModalityDoseRoute
Subject ALXN2350 Gene therapy (AAV / viral vector) — Intravenous

Indications

dilated cardiomyopathy 1HH